Hydroxyprogesterone Caproate

Pharmaceuticals -> Listed in ZINC15

Pharmaceutical

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Danger

H360 (93.2%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 7 notifications to the ECHA C&L Inventory.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Hydroxyprogesterone caproate

Ambiguous-DILI-concern

2

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

The mechanism by which progesterone prevents preterm birth is not well understood, but many pathways are likely involved. Progesterone plays a vital role in regulation of the female reproductive system and is important for successful implantation of the embryo and maintenance of pregnancy. It acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Progesterone binding to these receptors ultimately leads to regulation of gene transcription. This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with initiation of labor, and maintains uterine queiscence by stabilizing progesterone acting on the myometrium.

HYDROXYPROGESTERONE CAPROATE

Progesterone Congeners [CS]; Progestin [EPC]

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.

Absorption of 17-hydroxyprogesteron caproate is slow, occurring over a long period of time.

Following intramuscular injection, approximately 50% of hydroxyprogesterone caproate metabolites are eliminated in the feces, while approximately 30% of metabolites are eliminated in the urine.

Hydroxyprogesterone caproate has a high volume of distribution.

Clearance is highly variable from patient to patient.